CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH Despite being mostly low-grade, cytokine release syndrome, skin-related events, and dysgeusia were frequent side effects of talquetamab therapy. Patients who had multiple myeloma that was relapsed or resistant after receiving substantial prior treatment had a significant response to talquetamab.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
